BRENTUXIMAB VEDOTIN
Background and Date of Approval
Brentuximab vedotin is an approved medication used in the treatment of Hodgkin lymphoma, cutaneous T-cell lymphoma, and systemic anaplastic large cell lymphoma.
Uses
Brentuximab vedotin is used to treat various cancers, including classical Hodgkin lymphoma (both newly diagnosed and relapsed), systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, cutaneous T-cell lymphoma, and CD30-expressing mycosis fungoides, all in combination with other therapies.
How is it administered?
Brentuximab vedotin can be administered only as an intravenous injection into a vein by your physician in a hospital setting. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.
Side Effects
Brentuximab vedotin can cause serious side effects, including low blood cell counts, which can increase your risk of infection, bleeding, or bruising; tingling, numbness, or burning pain in your hands or feet; lung problems like cough, shortness of breath, or wheezing; high blood sugar; allergic reactions including rash, hives, swelling of the face, throat, or tongue, difficulty breathing; and serious skin reactions.
Warnings
Brentuximab vedotin could develop a serious brain infection called progressive multifocal leukoencephalopathy (PML), leading to disability or death. Your blood cell counts might drop, increasing your risk of infections, bleeding, or bruising. Your doctor will monitor your blood regularly. You could experience tingling, numbness, or burning pain in your hands or feet.
Precautions
Watch for new or worsening problems with speech, thought, vision, or muscle movement after taking Brentuximab vedotin, and tell your doctor immediately. Avoid activities that could increase your risk of getting sick, such as being around people with infections. Wear comfortable shoes and avoid activities that put pressure on your nerves. Report any bleeding or bruising, even minor ones.
Word of Advice
During treatment with brentuximab vedotin and for up to 6 months following the last dose, male patients are advised not to father a child. This precaution is observed to minimise potential serious risks to the fetus from medication exposure.
References
Takeda Pharma A/S, Electronic Medicines Compendium (EMC), [Revised on June 2022] [Accessed on 11 August 2023], https://www.medicines.org.uk/emc/files/pil.2859.pdf Adcetris 50mg injection. Macmillan Cancer Support, [Revised on 1 July 2022], [Accessed on 11 August 2023], www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/brentuximab Adcetris, INN- Adcetris 50mg injection. [Revised on 10 Jan 2023], [Accessed on 11 August 2023], www.ema.europa.eu/en/documents/product-information/www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf Seattle Genetics, Inc. US Food & Drug Administration. [Revised Nov 2014], [Accessed on 11 August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf
Frequently Asked Questions
What cancers is Brentuximab vedotin used to treat?
Brentuximab vedotin primarily treats classical Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. It may be used as a frontline treatment or when other treatments are ineffective.
How is Brentuximab vedotin administered?
Brentuximab vedotin is administered as an intravenous (IV) infusion by a physician in a clinical setting, such as a hospital or clinic.
What precautions should I take before starting Brentuximab vedotin?
Inform your physician about your medical history, medications, and allergies. Regular monitoring of blood counts and other relevant parameters may be necessary during treatment.
Can I drive or operate heavy machinery while on Brentuximab vedotin?
Brentuximab vedotin may cause fatigue or other side effects affecting your ability to drive or operate machinery. It's advisable to avoid such activities if you experience these effects.
What are the common side effects of Brentuximab vedotin?
Common side effects of Brentuximab vedotin may include fatigue, nausea, diarrhea, fever, muscle pain, swollen joints, and upper respiratory tract infections.